米国市場銘柄情報

TNDM タンデム・ダイアベティス・ケア

銘柄追加

37.380
+2.140+6.07%

取引中 04/29 10:31 ET

24.13億時価総額-10897直近PER

タンデム・ダイアベティス・ケアに関するコメント

ログインコメントを投稿

Moomoo AI

03/22 18:56

Despite losses and negative cash flow, the company's US$178.2m balance sheet allows for at least two years of growth spending. However, the stock is seen as risky due to these financial conditions.

Is Tandem Diabetes Care (NASDAQ:TNDM) Using Debt In A Risky Way?

Moomoo AI

03/04 18:44

Tandem Diabetes Care's share price rise sparks hope, but turnarounds can be risky. The gap between revenue and share price growth could warrant further investigation. Last year's performance suggests unresolved issues, as it underperformed the annualised 10% loss over the past five years.

Investors Are Selling off Tandem Diabetes Care (NASDAQ:TNDM), Lack of Profits No Doubt Contribute to Shareholders Three-year Loss

Moomoo AI

01/28 20:57

The stock is undervalued, indicating a potential buy opportunity. The company's positive future outlook and expected earnings increase aren't fully reflected in the current share price. Consider the company's financial health as well.

What Is Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Share Price Doing?

Moomoo AI

2023/11/26 21:32

Despite the good rate of top-line growth at Tandem Diabetes Care, the severe share price drop indicates the company's losses might be larger than expected. Given the stock's past poor performance, there may be unresolved challenges the company is facing.

Tandem Diabetes Care (NASDAQ:TNDM) Three-year Losses Have Grown Faster Than Shareholder Returns Have Fallen, but the Stock Rises 7.1% This Past Week

Moomoo AI

2023/11/03 01:42

Analysts from Citi and Barclays revised their price targets for TNDM following reduced full-year revenue guidance despite strong Q3 results. Citi's Joanne Wuensch reduced her target from $23 to $18, while Barclays' Matt Miksic, citing poor international sales, lowered his target from $62 to $39.

Tandem Diabetes Hits 52-week After Guidance Cut

Meltyy

2023/10/16 11:18

Stock Markets Rocked as Weight Loss Sweeps the Globe

Weight loss drugs lead the stock market
As GLP-1 diet drug companies have grown in influence, they have grown to be the new leaders of the stock market.
$ノボ・ノルディスク(NVO.US)$ , with Wegovy and Ozempic in hand, is now Europe's largest company with a market capitalization of $433 billion, and the Danish drug giant's rapid growth has even had a direct impact on the Danish krone exchange rate and interest rates.